Our patented JAA-F11 antibody is a targeted immunotherapy for primary and metastatic breast cancer including triple negative subtypes, meeting an unmet need.
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free